Precision Optics Corporation, Inc. (POCI) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call indicates strong revenue growth, especially in key manufacturing programs, and an optimistic outlook for fiscal 2026 with improved gross margins and positive adjusted EBITDA. The Q&A section did not reveal significant negative trends, and the company's strategic expansion into defense aerospace alongside medical devices suggests diversification and potential profitability. Despite some concerns over gross margins and delayed orders, the overall sentiment is positive, supported by strong revenue expectations and strategic operational investments.
Key Financial Performance
Quarterly Revenue $6.7 million, a 46% increase year-over-year (net of tariff reimbursements). The increase was driven by two key manufacturing programs: one with a top-tier aerospace company and another with a surgical robotics company for a single-use cystoscope.
Aerospace Program Revenue $2.5 million (net of tariffs), an increase of more than 800% year-over-year. Growth was supported by a $9 million backlog and increased production throughput due to a recent line expansion.
Cystoscope Program Revenue $1.5 million (net of tariffs), an 85% increase compared to the previous quarter and a 180% increase year-over-year. Growth was attributed to strong end-market demand and resolution of prior production issues.
Ross Optical Division Revenue Over $1 million, a 10% quarter-over-quarter increase. Growth was supported by existing staff and infrastructure, indicating a potential recovery in the optical components market.
Gross Margins 14.4%, compared to 12.9% in the prior quarter and 26.6% a year ago. Margins were impacted by under-absorption of engineering resources and delays in receiving a large defense customer reorder.
Product Development Revenue $656,000, the lowest in many years, due to the transition of programs from development to production. Recovery is expected with a 50%-75% quarter-over-quarter increase in Q2.
Operating Expenses (OpEx) $2.5 million, compared to $2.4 million a year ago. SG&A expenses increased due to one-time items like $184,000 in employee severance and higher stock-based compensation.
Adjusted EBITDA Negative $1.2 million, compared to negative $1.0 million a year ago. The decline was due to lower gross margins and higher operating expenses.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Augmented reality systems for defense applications: Signed a new development agreement for augmented reality systems, broadening exposure to aerospace and defense industries.
High-resolution borescope for jet engine inspection: Signed a new development agreement for a borescope with high-resolution capabilities for jet engine inspection, targeting aerospace industry.
Aerospace program: Achieved record quarterly revenue of $2.5 million (net of tariffs), an 800% increase year-over-year, with a backlog of over $9 million.
Single-use cystoscope program: Revenue increased to $1.5 million (net of tariffs), an 85% increase quarter-over-quarter and 180% year-over-year, driven by strong end-market demand.
Production infrastructure improvements: Expanded production line for aerospace program, increasing throughput by 50%. Enhanced cystoscope production systems to improve yield and efficiency.
Gross margin improvements: Negotiated tariff reimbursements and pricing adjustments for key programs, leading to improved gross margins.
Sales and marketing enhancements: Implemented new marketing strategies, including social media, webinars, and AI tools, resulting in new high-probability leads.
Transition to scaled production: Focused on scaling production capabilities to handle higher volumes, ensuring long-term operational efficiency and profitability.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Gross Margin Challenges: The company is facing gross margin challenges due to the aggressive ramp-up of production operations. This includes the need to build infrastructure, processes, and talent to scale, which has stressed the organization and increased costs.
Production Scaling Issues: The transition to higher production volumes has been challenging, requiring significant changes in team, infrastructure, and processes. The company underestimated the extent of these changes, which has impacted efficiency and margins.
Under-Absorption of Resources: The micro-optics and product development divisions suffered from under-absorption of resources due to unusually low revenue in the first quarter, negatively impacting margins.
Delayed Customer Orders: A significant reorder from a major defense contractor for the micro-optics division has been delayed, causing revenue and margin shortfalls.
Tariff Costs: Tariffs on sourced components have added costs, although some customers have agreed to reimburse these on a pass-through basis.
Dependence on Key Programs: The company’s financial performance is heavily reliant on a few key programs, such as the aerospace and cystoscope programs. Any disruption in these programs could significantly impact revenue.
Operational Growing Pains: The company is experiencing growing pains as it transitions to higher production volumes, including the need for updated systems and processes to handle increased demand.
Economic and Market Uncertainties: The optical components market has been impacted by tariffs and other uncertainties, leading to delayed customer orders and cautious spending.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: Precision Optics expects fiscal year 2026 revenue to exceed $25 million, supported by record revenue levels in systems manufacturing and a growing product development pipeline.
Adjusted EBITDA: The company anticipates approximately $0.5 million of positive adjusted EBITDA for fiscal year 2026, despite a first-quarter loss.
Aerospace Program Growth: Revenue for the aerospace program is expected to continue growing through fiscal 2026, supported by a $9 million backlog and a recent production line expansion increasing throughput by 50%.
Cystoscope Program Margins: Margins for the single-use cystoscope program are expected to improve quarter-over-quarter throughout fiscal 2026 due to production efficiency gains, pricing updates, and tariff reimbursements.
Product Development Pipeline: The product development division is expected to recover, with a 50%-75% quarter-over-quarter revenue increase in Q2 and additional growth in Q3 and Q4. New programs include augmented reality systems for defense and high-resolution borescopes for jet engine inspection.
Micro-Optics Division: Revenue and margins for the Micro-Optics division are expected to improve in Q2, driven by a delayed defense contract order and increased resource utilization.
Ross Optical Division: The Ross Optical division is cautiously optimistic about a recovery in the optical components market, with strong backlog and consecutive quarter-over-quarter revenue increases.
Operational Improvements: The company expects ongoing improvements in production efficiency and gross margins across major programs, contributing to profitability in fiscal 2026 and beyond.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividends: These improvements will pay dividends as more programs transfer to production, and we continue to ramp this part of the business into the future. This development of a scaled production capability should, over time, be value creating for shareholders.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Are the two new development programs in defense and aerospace applications a pivot for the company?
A:The company is not pivoting away from the medical device space but is promoting itself more in the defense aerospace marketplace. The two new programs are due to random timing, and future announcements may still involve medical devices. Defense aerospace programs can move faster due to fewer regulatory requirements and can be very profitable.
Q:What is the company's capacity utilization outlook for the end of 2026?
A:The company is updating its Gardner, Massachusetts production facility, which may be completed by the end of fiscal 2026 or slip into fiscal 2027. Once completed, the company will have enough capacity to double its current size before incurring significant expansion costs.
Q:Can the company break out its COGS in terms of labor, materials, and overhead? Can production be further automated?
A:Automation opportunities exist but require volumes roughly double the current levels to justify costs. For COGS, manufacturing has significant material and labor costs, micro-optics lab is labor-intensive, product development is engineering-based, and Ross Optical is primarily material-based with fixed labor costs.
Q:What caused the delay in the legacy defense program reorder?
A:The exact cause is unknown, but it may be related to government activities or shutdowns. The company has experienced similar delays in the past due to government shutdowns.
Q:What are the average lifespans of defense versus medical programs?
A:Medical device programs typically last at least 5 years, often much longer due to high barriers to change. Defense programs also tend to last 5-10 years or more, as they involve high-tech components with high start-up costs and risk aversion to changes.
Q:What is the timeline and dollar volume for the manufacturing move from Maine to Gardner?
A:One production line was moved, with tools and fixtures reinstalled. The program, previously generating $1 million annually, is expected to resume in the next few months and grow from there.
Q:How many new hires were made in the last 3 months, and how many are expected in the next 3 months?
A:Approximately 20 hires were made in the last 3 months, including 15 direct labor roles and 4-5 management/engineering roles. A similar number of hires is expected in the next 3-6 months.
Q:Can you provide more details about the borescope program?
A:The borescope is custom-made for a jet engine manufacturer and will be sold alongside their jet engines. The manufacturer produces a large number of jet engines, indicating significant potential for the borescope program.
Q:Review of Unclear Management Responses
A:The management avoided directly answering the question about capacity utilization at the end of 2026, instead discussing the timeline for facility updates and potential capacity expansion without providing specific revenue support details.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Aerospace program
Micro optic
Ross division
approval
benefit investment
borescope
customer program
cystoscope line
cystoscope program
debt
defense reorder
expansion
frame
improvement
increase product
increase program
industry
infrastructure process
inspection
jet engine
margin increase
market order
minute
momentum
net tariff
optic division
product customer
production sale
profitability
program increase
progress
reality system
recovery
reimbursement increase
remainder
resolution
system result
POCI Transcript
Precision Optics Corporation, Inc. (POCI) Q3 2026 Earnings Call Transcript
Positive5-13
The company increased revenue guidance, expects strong future growth, and achieved breakeven this quarter. Despite a temporary slowdown in aerospace, other programs are expected to offset this. The Q&A reveals positive sentiment from analysts, who are reassured by management's long-term growth plans and profitability expectations. The company's strategic developments, such as the Unity platform and facility expansions, further bolster a positive outlook. Overall, these factors suggest a positive stock price movement over the next two weeks.
Precision Optics Corporation, Inc. (POCI) Q2 2026 Earnings Call Transcript
Unknown2-17
Despite some positive developments in the aerospace and cystoscope programs, the company faces significant challenges. Declining gross margins, increased net loss, and negative EBITDA signal financial strain. The Q&A section revealed uncertainties about equity financing and loan success, which could lead to dilution. The strong demand and production improvements may not offset the immediate financial issues, leading to a negative sentiment and potential stock price decline.
Precision Optics Corporation, Inc. (POCI) Q1 2026 Earnings Call Transcript
Positive11-13
The earnings call indicates strong revenue growth, especially in key manufacturing programs, and an optimistic outlook for fiscal 2026 with improved gross margins and positive adjusted EBITDA. The Q&A section did not reveal significant negative trends, and the company's strategic expansion into defense aerospace alongside medical devices suggests diversification and potential profitability. Despite some concerns over gross margins and delayed orders, the overall sentiment is positive, supported by strong revenue expectations and strategic operational investments.
Precision Optics Corporation, Inc. (POCI) Q4 2025 Earnings Call Transcript
Positive9-29
The earnings call reveals record-high quarterly revenue and a significant increase in production revenue, despite a decline in gross margin. The Q&A section confirms conservative but optimistic guidance, with expectations of improved gross margins and a well-prepared pipeline. Management's clear responses and strategic focus on production and engineering projects suggest a positive outlook. The stock price is likely to react positively, with potential gains of 2% to 8% over the next two weeks.
POCI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
